Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
all decrease » small decrease (Expand Search), a decrease (Expand Search), awd decreased (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
Showing 1 - 20 results of 4,241 for search '(( significant ((all decrease) OR (fold decrease)) ) OR ( significant gap decrease ))', query time: 0.41s Refine Results
  1. 1
    Catalytic fold of WT PARG1 C1-GAP domain for RhoA interaction.

    Catalytic fold of WT PARG1 C1-GAP domain for RhoA interaction. by Zen Kouchi (14898435)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)).

    Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)). by Mobina Faqani (22783963)

    Published 2025
    “…<p>Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)).…”
    Save to List
    Saved in:
  3. 3
    Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease).

    Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease). by Mobina Faqani (22783963)

    Published 2025
    “…<p>Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease).…”
    Save to List
    Saved in:
  4. 4
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 5
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 6
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 7
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 8
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 9
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  10. 10
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 11
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  12. 12
    MiR-129-5p levels were decreased in mouse depression models.

    MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

    Published 2025
    “…The Y-axis represents the fold change, while the X-axis indicates the significance of differential expression. …”
    Save to List
    Saved in:
  13. 13
    a) FB image processing featuring (1) FB map, (2) TWOMBLI mask, (3) FB-mask multiplied image, and (4) Ridge detection selection of contours. b) TWOMBLI Output Descriptions. (1) Area: cross-sectional area of all fibers, (2) Lacunarity: number and size of gaps in the ECM, (3) Total Length: sum length of all drawn fibers, (4) Endpoints: sum of fiber terminus points, (5) Hyphal Growth Unit: number of end points per unit length, (6) Branchpoints: number of fiber intersections, (7) Box-Counting Fractal Dimension: indicates self-similarity and space-filling properties, (8) Curvature: change in angle moving along individual fibers, (9) Percent High-Density Matrix: proportion of white pixels with respect to dark pixels, (10) Alignment: degree to which fibers are oriented in a similar direction.

    a) FB image processing featuring (1) FB map, (2) TWOMBLI mask, (3) FB-mask multiplied image, and (4) Ridge detection selection of contours. b) TWOMBLI Output Descriptions. (1) Area... by Zoë Dinkel (21402766)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Settling time for changes in the median of the Folded Normal distribution.

    Settling time for changes in the median of the Folded Normal distribution. by Ariel Burman (20329776)

    Published 2024
    Save to List
    Saved in:
  15. 15
    Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia disorder.

    Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1.

    IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. by Iratxe Zuazo-Gaztelu (21071939)

    Published 2025
    Save to List
    Saved in:
  17. 17
    Summary of structural dynamics of WT and mutant RhoGAPs-RhoA complexes.

    Summary of structural dynamics of WT and mutant RhoGAPs-RhoA complexes. by Zen Kouchi (14898435)

    Published 2025
    Save to List
    Saved in:
  18. 18
    Table 1_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx

    Table 1_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx by Fengwang Xue (22245625)

    Published 2025
    “…Further validation using RCS analysis revealed a robust inverse relationship between PNI scores and ACM, and subgroup analyses revealed no significant interactions.</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…”
    Save to List
    Saved in:
  19. 19
    Table 2_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx

    Table 2_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx by Fengwang Xue (22245625)

    Published 2025
    “…Further validation using RCS analysis revealed a robust inverse relationship between PNI scores and ACM, and subgroup analyses revealed no significant interactions.</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…”
    Save to List
    Saved in:
  20. 20
    Table 3_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx

    Table 3_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx by Fengwang Xue (22245625)

    Published 2025
    “…Further validation using RCS analysis revealed a robust inverse relationship between PNI scores and ACM, and subgroup analyses revealed no significant interactions.</p>Conclusion<p>Among pneumonia patients receiving glucocorticoid therapy, a decreased PNI was associated with an increased risk of 30-day and 90-day mortality, particularly in those with a PNI < 43.…”
    Save to List
    Saved in:

Search Tools: